ID   H4
AC   CVCL_1239
SY   H-4
DR   BTO; BTO:0003704
DR   CLO; CLO_0003599
DR   EFO; EFO_0002184
DR   CLDB; cl5193
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-148
DR   BCRJ; 0263
DR   BioGRID_ORCS_Cell_line; 430
DR   BioSample; SAMN03472722
DR   BioSample; SAMN10987915
DR   cancercelllines; CVCL_1239
DR   CCRID; 1101HUM-PUMC000372
DR   CCRID; 4201HUM-CCTCC00128
DR   CCTCC; GDC0128
DR   Cell_Model_Passport; SIDM00852
DR   ChEMBL-Cells; CHEMBL3308507
DR   ChEMBL-Targets; CHEMBL1075452
DR   CLS; 300184
DR   Cosmic; 687571
DR   Cosmic; 849856
DR   Cosmic; 907042
DR   Cosmic; 1610749
DR   Cosmic; 1746955
DR   Cosmic; 2060805
DR   Cosmic; 2302320
DR   Cosmic; 2367529
DR   Cosmic-CLP; 907042
DR   DepMap; ACH-000389
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS381KGR
DR   ENCODE; ENCBS836LDB
DR   ENCODE; ENCBS902ISQ
DR   GDSC; 907042
DR   GEO; GSM326236
DR   GEO; GSM887031
DR   GEO; GSM888101
DR   GEO; GSM1669834
DR   IARC_TP53; 21355
DR   IGRhCellID; H4
DR   IZSLER; BS TCL 102
DR   KCB; KCB 2012027YJ
DR   LiGeA; CCLE_383
DR   LINCS_LDP; LCL-1401
DR   Lonza; 285
DR   PharmacoDB; H4_437_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1239
DR   PubChem_Cell_line; CVCL_1239
DR   TOKU-E; 1367
DR   Wikidata; Q54872126
RX   DOI=10.1007/0-306-46861-1_11;
RX   PubMed=4544026;
RX   PubMed=6256643;
RX   PubMed=6500159;
RX   PubMed=10074188;
RX   PubMed=10560660;
RX   PubMed=11414198;
RX   PubMed=11508811;
RX   PubMed=19435942;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-293.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   HLA typing: A*03:01,30:02; B*08:01,18:01; C*05:01,07:01; DQB1*02:02,02:02; DRB1*03:01,03:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10560660).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP=907042; DepMap=ACH-000389).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=1.32%; East Asian, North=0.97%; East Asian, South=0%; South Asian=0%; European, North=68.05%; European, South=29.66% (PubMed=30894373).
CC   Miscellaneous: Originally classified as originating from a neuroglioma, an obsolete classification. This cell line has been reclassified as an astrocytoma.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): ATCC=HTB-148; CCRID; CLS=300184; Cosmic-CLP=907042
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 14,16
ST   D19S433: 12,14
ST   D21S11: 30,31
ST   D2S1338: 18,25
ST   D3S1358: 17,18
ST   D5S818: 10,12
ST   D7S820: 8,11
ST   D8S1179: 9,12 (ATCC=HTB-148; CCRID)
ST   D8S1179: 14 (CLS=300184)
ST   FGA: 19,25
ST   Penta D: 10,12
ST   Penta E: 5,12
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 42
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=4544026; DOI=10.1093/jnci/52.1.71;
RA   Arnstein P., Taylor D.O.N., Nelson-Rees W.A., Huebner R.J.,
RA   Lennette E.H.;
RT   "Propagation of human tumors in antithymocyte serum-treated mice.";
RL   J. Natl. Cancer Inst. 52:71-84(1974).
//
RX   PubMed=6256643; DOI=10.1038/288724a0;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.;
RT   "Defective repair of alkylated DNA by human tumour and
RT   SV40-transformed human cell strains.";
RL   Nature 288:724-727(1980).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=10074188; DOI=10.1128/JVI.73.4.3338-3350.1999;
RA   Arbour N., Cote G., Lachance C., Tardieu M., Cashman N.R.,
RA   Talbot P.J.;
RT   "Acute and persistent infection of human neural cell lines by human
RT   coronavirus OC43.";
RL   J. Virol. 73:3338-3350(1999).
//
RX   PubMed=10560660; DOI=10.1097/00005072-199911000-00007;
RA   Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L.,
RA   Collins V.P.;
RT   "Mutational profile of the PTEN gene in primary human astrocytic
RT   tumors and cultivated xenografts.";
RL   J. Neuropathol. Exp. Neurol. 58:1170-1183(1999).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11508811; DOI=10.1023/A:1010680920087;
RA   Krex D., Mohr B., Hauses M., Ehninger G., Schackert H.K.,
RA   Schackert G.;
RT   "Identification of uncommon chromosomal aberrations in the neuroglioma
RT   cell line H4 by spectral karyotyping.";
RL   J. Neurooncol. 52:119-128(2001).
//
RX   PubMed=19435942; DOI=10.1215/15228517-2009-025;
RA   Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R.,
RA   Jones D.T.W., Collins V.P.;
RT   "IDH1 mutations are present in the majority of common adult gliomas
RT   but rare in primary glioblastomas.";
RL   Neuro-oncol. 11:341-347(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//